The blood-brain barrier excludes most peptides effectively, and the strategies that work all involve trade-offs rather than a clean solution.
Key Takeaways
- Tight junctions between endothelial cells block paracellular passage, and efflux transporters actively remove many molecules that do enter.
- Nasal administration can provide some direct access along olfactory and trigeminal pathways, bypassing the barrier partially.
- Cerebrospinal fluid concentration is not the same as brain interstitial concentration, and plasma-to-brain ratios are frequently misreported.
Why the barrier is effective
Tight junctions between endothelial cells block paracellular passage, and efflux transporters actively remove many molecules that do enter. Peptides face both a physical and an active barrier, which is why central exposure is typically a tiny fraction of plasma exposure.
Receptor-mediated transcytosis
Conjugating a peptide to a ligand for transferrin or insulin receptors can carry it across through vesicular transport. This is the most actively pursued strategy and has produced clinical candidates, though efficiency remains low.
For related mechanism work, see peptide-drug conjugates.
Intranasal route to the CNS
Nasal administration can provide some direct access along olfactory and trigeminal pathways, bypassing the barrier partially. The delivered fraction is small and variable, and the route should not be oversold in research contexts.
Direct administration approaches
Intrathecal and intracerebroventricular routes bypass the barrier entirely at the cost of invasiveness. They are appropriate for severe conditions where the risk is justified and are used in clinical practice for selected molecules.
Measuring central exposure honestly
Cerebrospinal fluid concentration is not the same as brain interstitial concentration, and plasma-to-brain ratios are frequently misreported. State which compartment was sampled and what the measurement actually represents.
Experimental Conditions and Practical Setup
Central exposure is assessed by sampling both plasma and the relevant compartment, with the analyst stating which one was measured. Brain homogenate, cerebrospinal fluid, and microdialysate give different values, and reporting a single ratio without naming the compartment makes the result impossible to compare with other work.
Delivery routes and what they trade
| Route | Advantage | Cost |
|---|---|---|
| Receptor-mediated transcytosis | Uses physiological transport | Low efficiency |
| Intranasal | Non-invasive | Small, variable fraction |
| Intrathecal or intracerebroventricular | Bypasses the barrier | Invasive |
| Barrier disruption | Broad access | Tolerability and specificity concerns |
Practical Notes for the Bench
- Do not treat CSF concentration as equivalent to brain interstitial concentration.
- Report which compartment was sampled when quoting central exposure.
- Weigh invasiveness against delivery efficiency for each application.
Frequently Asked Questions
Can peptides cross the blood-brain barrier?
Only to a very limited extent unaided, because tight junctions and efflux transporters both restrict passage.
Does intranasal delivery reach the brain?
Partially, along olfactory and trigeminal pathways, but the fraction is small and variable.
Is CSF a good surrogate for brain exposure?
No. Cerebrospinal fluid and brain interstitial concentrations differ and should not be used interchangeably.
Is cerebrospinal fluid concentration a good surrogate for brain exposure?
No. Cerebrospinal fluid and brain interstitial fluid differ, and the two should not be used interchangeably when reporting central exposure.
Related Reading
- peptide-drug conjugates
- peptide vaccine design
- peptide stapling technology
- amylin pramlintide
- TB-500 thymosin beta-4
References & Further Reading
- Han EL et al. Peptide-Functionalized Lipid Nanoparticles for Targeted Systemic mRNA Delivery to the Brain. Nano Lett. 2025. PubMed 39688915
- Zhou X et al. Brain penetrating peptides and peptide-drug conjugates to overcome the blood-brain barrier and target CNS diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021. PubMed 33470550
- Tong H et al. Optimizing Peptide-Conjugated Lipid Nanoparticles for Efficient siRNA Delivery across the Blood-Brain Barrier and Treatment of Glioblastoma Multiforme. ACS Chem Biol. 2025. PubMed 40080657
- Peptide literature search on PubMed
- Full-text archive at PubMed Central
- FDA guidance documents on peptide drug products
All material on this page is intended for laboratory research and educational reference only. It is not medical advice, and it does not describe any approved diagnostic or therapeutic use.
Reviewed by Dr. Marcus Feld, Molecular Pharmacology, In Vitro Models.